China-based late-stage biopharmaceutical company Minghui Pharmaceutical announced on Friday positive topline results from its phase III trial of MH004 (tofacitinib etocomil) ointment 1.0%, a pan-Jak inhibitor, for mild to moderate atopic dermatitis (AD) in adolescents and adults.

The randomized, vehicle-controlled study included 377 participants treated over eight weeks, followed by a 44-week open-label safety extension.

Primary endpoints showed 41.0% of MH004-treated participants achieved Investigator Global Assessment-Targeted Success (IGA-TS) at Week 4, compared to 10.3% with vehicle (P